Scarica l'app Stockscreener
61.85
0.74%
-0.46
Dopo l'orario di chiusura:
61.80
-0.05
-0.08%
Precedente Chiudi:
$62.31
Aprire:
$62.32
Volume 24 ore:
22,622
Relative Volume:
0.51
Capitalizzazione di mercato:
$1.97B
Reddito:
-
Utile/perdita netta:
$-32.61M
Rapporto P/E:
-52.67
EPS:
-1.1742
Flusso di cassa netto:
-
1 W Prestazione:
+1.41%
1M Prestazione:
+3.64%
6M Prestazione:
+4.09%
1 anno Prestazione:
+28.53%
Intervallo 1D:
$61.01
$62.48
Intervallo di 1 settimana:
$59.12
$62.64
Portata 52W:
$43.70
$86.53
Belite Bio Inc Adr Stock (BLTE) Company Profile
Nome
Belite Bio Inc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta BLTE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
61.85 | 1.94B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-12-14 | Iniziato | Maxim Group | Buy |
| 2023-07-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Iniziato | SVB Securities | Outperform |
| 2022-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-01 | Iniziato | The Benchmark Company | Buy |
Belite Bio Inc Adr Borsa (BLTE) Ultime notizie
Belite Bio Executives Share Latest Retinal Disease Breakthroughs at BTIG Biotech Conference - Stock Titan
New Strong Sell Stocks For July 22nd - Barchart.com
New Strong Sell Stocks for July 22nd - Zacks Investment Research
What analysts say about Belite Bio Inc Depositary Receipt stockConsistent wealth multiplication - jammulinksnews.com
Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant - Eyes On Eyecare
Stargardt Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Q2 EPS Estimates for Belite Bio Decreased by Leerink Partnrs - Defense World
Ouster Announces Date for Second Quarter 2025 Earnings Call - The Globe and Mail
Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential - TipRanks
Phase 3 PHOENIX trial for oral GA treatment completes enrollment - Modern Retina
Belite Bio stock maintains Buy rating at H.C. Wainwright on trial progress - Investing.com India
Belite Bio Completes Enrollment for Phase 3 PHOENIX Trial on Tinlarebant - TipRanks
Major Breakthrough: First-Ever Oral Treatment for Geographic Atrophy Reaches Full Phase 3 Enrollment - Stock Titan
Analysts Issue Forecasts for Belite Bio FY2026 Earnings - Defense World
Reviewing Belite Bio (NASDAQ:BLTE) & ZyVersa Therapeutics (NASDAQ:ZVSA) - Defense World
Bank of America Corp DE Acquires 4,891 Shares of Belite Bio, Inc (NASDAQ:BLTE) - Defense World
Cohen & Company Inc. (NYSEAMERICAN:COHN) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Belite Bio, Inc (NASDAQ:BLTE) Shares Sold by Citadel Advisors LLC - Defense World
BNP Paribas Financial Markets Acquires New Shares in Belite Bio, Inc (NASDAQ:BLTE) - Defense World
What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World
What is HC Wainwright's Estimate for Belite Bio Q2 Earnings? - MarketBeat
Belite Bio stock holds $80 target on FDA breakthrough nod By Investing.com - Investing.com Nigeria
Belite Bio stock holds $80 target on FDA breakthrough nod - Investing.com
Belite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating - TipRanks
Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress - TipRanks
Why Belite Bio’s Stock is Soaring High - TipRanks
Belite Bio’s Tinlarebant Receives FDA Breakthrough Therapy Designation for Stargardt Disease - TipRanks
Belite Bio Says FDA Grants Breakthrough Therapy Tag to Stargardt Disease Drug - marketscreener.com
Belite Bio Announces FDA Granting Of Breakthrough Therapy Designation For Tinlarebant For The Treatment Of Stargardt Disease - marketscreener.com
Belite Bio Receives FDA Breakthrough Therapy Designation for Tinlarebant in Treating Stargardt Disease - Nasdaq
Belite Bio Announces FDA Granting of Breakthrough Therapy - GlobeNewswire
Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Arcellx Inc (ACLX) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail
Q2 Earnings Estimate for Belite Bio Issued By HC Wainwright - Defense World
Belite Bio (NASDAQ:BLTE) Earns “Overweight” Rating from Cantor Fitzgerald - Defense World
HC Wainwright Reaffirms Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World
Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - GlobeNewswire
Benchmark maintains Buy on Belite Bio stock, $80 price target unchanged - Investing.com Nigeria
Belite Bio’s Earnings Call Highlights Clinical Progress and Financial Strength - TipRanks
Belite Bio at Deutsche Bank Conference: Promising Drug Trials By Investing.com - Investing.com India
Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference, May-15-2025 12 - marketscreener.com
Belite Bio at Deutsche Bank Conference: Promising Drug Trials - Investing.com
Belite Bio stock retains Overweight rating at Cantor Fitzgerald - Investing.com Australia
Belite Bio stock retains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com India
Promising Clinical Trials and Strategic Developments Justify Buy Rating for Belite Bio - TipRanks
Belite Bio Advances Clinical Trials Amid Financial Challenges - TipRanks
Earnings call transcript: Belite Bio’s Q1 2025 sees narrower EPS loss - Investing.com Nigeria
Earnings Flash (BLTE) Belite Bio Q1 Loss $0.45 Vs. FactSet Est. $0.35 Loss - marketscreener.com
Belite Bio Q1 2025 Earnings Call Transcript - MarketBeat
Belite Bio Advances Tinlarebant Trials with Positive Interim Results - TipRanks
Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Belite Bio Inc Adr Azioni (BLTE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):